Maxim Group Upgrades Theriva Biologics (TOVX) to Buy, PT $1
Tweet
Share
E-mailGet Alerts TOVX Hot Sheet
Price: $0.23 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy upgraded Theriva Biologics (NYSE: TOVX) from Hold to Buy with a price target of $1.00.
For an analyst ratings summary and ratings history on Theriva Biologics click here. For more ratings news on Theriva Biologics click here.
Shares of Theriva Biologics closed at $0.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stripe, Advent In Talks To Buy Paypal - WSJ
- Aurora Spine settles patent dispute, secures $600K insider loan
- Berkshire adds significantly to Alphabet position, starts small position in DR Horton
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Maxim Group, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
